Metabolic syndrome and cardiometabolic risk: An update

References

• Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575–581
   PubMed Web of Science ®Google Scholar
• Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 2160–2167
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438
   PubMed Web of Science ®Google Scholar
• Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch‐Johnsen K, Pyorala K. for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all‐cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066–1076
   PubMed Web of Science ®Google Scholar
• Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non‐traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14: 686–695
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle‐aged men. JAMA 2002; 288: 2709–2716
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP‐defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210–1214
   PubMed Web of Science ®Google Scholar
• Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C‐reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all‐causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309–314
   PubMed Web of Science ®Google Scholar
• Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817–1822
   PubMed Web of Science ®Google Scholar
• Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136–141
   PubMed Web of Science ®Google Scholar
• Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–1250
   PubMed Web of Science ®Google Scholar
• Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10‐year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–673
   PubMed Web of Science ®Google Scholar
• Burke GL, Bertoni AG, Shea S, Tracy R, Watson KE, Blumenthal RS, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi‐Ethnic Study of Atherosclerosis. Arch Intern Med 2008; 168: 928–935
   PubMed Web of Science ®Google Scholar
• Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/NationalHeart Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551–556
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Clinical Practice Recommendations 2005. Diabetes Care 2005; 28: 1–79
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre‐diabetes, and cardiovascular diseases: Executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16: 135–232
   PubMed Web of Science ®Google Scholar
• Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. Diab Vasc Dis Res 2004; 1: 68–75
   PubMedGoogle Scholar
• Day C, Metabolic syndrome. or what you will: definitions and epidemiology. Diab Vasc Dis Res 2007; 4: 32–38
   PubMedGoogle Scholar
• Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497
   PubMed Web of Science ®Google Scholar
• Navarro J, Redón J, Cea‐Calvo L, Lozano JV, Fernández‐Pérez C, Bonet A, et al. Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC‐HTA study. Blood Press 2007; 16: 20–27
   PubMed Web of Science ®Google Scholar
• Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40–47
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation: the IDF consensus worldwide definition of the metabolic syndrome [article online], 2005. Available from http://www.idf.org/webdata/docs/metac_syndrome_def.pdf
   Google Scholar
• Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow‐up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111: 1777–1783
   PubMed Web of Science ®Google Scholar
• Meigs JB, D'Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46: 1594–1600
   PubMed Web of Science ®Google Scholar
• Anderson KM, Wilson PW, Odell PM, Kanne WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356–362
   PubMed Web of Science ®Google Scholar
• Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 1988; 77: 504–514
   PubMed Web of Science ®Google Scholar
• Mancia G, Bombelli M, Lanzarotti A, Grassi G, Cesana G, Zanchetti A, Sega R. Systolic versus diastolic blood pressure control in the hypertensive patients of the PAMELA population. Arch Intern Med 2002; 162: 582–586
   PubMedGoogle Scholar
• Björntorp P, Holm G, Rosmond R, Folkow B. Hypertension and the metabolic syndrome: closely related central origin. Blood Press 2000; 9: 71–82
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008; 21: 500–508
   PubMed Web of Science ®Google Scholar
• Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004; 93: 40–44
   PubMed Web of Science ®Google Scholar
• Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001; 103: 102–107
   PubMed Web of Science ®Google Scholar
• Bella JN, Devereux RB, Roman MJ, Palmieri V, Liu JE, Paranicas M, et al. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol 2001; 87: 1260–1265
   PubMed Web of Science ®Google Scholar
• Devereux RB, de Simone G, Palmieri V, Oberman A, Hopkins P, Kitzman DW, et al. Relation of insulin to left ventricular geometry and function in African American and white hypertensive adults: the HyperGEN study. Am J Hypertens 2002; 15: 1029–1035
   PubMed Web of Science ®Google Scholar
• Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK, Jones DW, et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2005; 112: 819–827
   PubMed Web of Science ®Google Scholar
• du Cailar G, Ribstein J, Mimran A. Left ventricular contractility and insulin resistance in essential hypertension. Blood Press 1995; 4: 23–31
   PubMedGoogle Scholar
• Cuspidi C, Meani S, Fusi V, Valerio C, Catini E, Sala C, et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875–882
   PubMed Web of Science ®Google Scholar
• Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Quarti‐Trevano F, et al. Long‐term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008; 26: 1602–1611
   PubMed Web of Science ®Google Scholar
• Cioffi G, Mureddu GF, Stefenelli C, de Simone G. Relationship between left ventricular geometry and left atrial size and function in patients with systemic hypertension. J Hypertens 2004; 22: 1589–1596
   PubMed Web of Science ®Google Scholar
• De Simone G, Devereux RB, Daniels SR, Mureddu G, Roman MJ, Kimball TR, et al. Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 1997; 95: 1837–1843
   PubMed Web of Science ®Google Scholar
• Høieggen A, Fossum E, Nesbitt SD, Palmieri V, Kjeldsen SE, Blood viscosity. plasma adrenaline and fasting insulin in hypertensive patients with left ventricular hypertrophy. ICARUS, a LIFE Substudy. Insulin CARotids US Scandinavica. Blood Press 2000; 9: 83–90
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995; 92: 835–841
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218–223
   PubMed Web of Science ®Google Scholar
• Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116: 6–12
   PubMed Web of Science ®Google Scholar
• Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000; 279: H234–H237
   Web of Science ®Google Scholar
• Erbay E, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome. Curr Atheroscler Rep 2007; 9: 222–229
   PubMedGoogle Scholar
• Tsai WC, Lin CC, Huang YY, Chen JY, Chen JH. Association of increased arterial stiffness and inflammation with proteinuria and left ventricular hypertrophy in non‐diabetic hypertensive patients. Blood Press 2007; 16: 270–275
   PubMed Web of Science ®Google Scholar
• Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51: 527–539
   PubMed Web of Science ®Google Scholar
• Ruan X, Zheng F, Guan Y. PPARs and the kidney in metabolic syndrome. J Physiol Renal Physiol 2008; 294: 1032–1047
   Google Scholar
• Sarzani R, Salvi F, Dessì‐Fulgheri P, Rappelli A. Renin‐angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26: 831–843
   PubMed Web of Science ®Google Scholar
• Alessi MC, Juhan‐Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995–1000
   PubMed Web of Science ®Google Scholar
• Barness LA, Opitz JM, Gilbert‐Barness E. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet. (Suppl A) 2007; 143: 3016–3034
   Google Scholar
• Fossum E, Berge KE, Høieggen A, Moan A, Rostrup M, Kjeldsen SE, et al. Polymorphisms in candidate genes for blood pressure regulation in young men with normal or elevated screening blood pressure. Blood Press 2001; 10: 92–100
   PubMed Web of Science ®Google Scholar
• Carter KW, Hung J, Powell BL, Wiltshire S, Foo BT, Leow YC, et al. Association of Interleukin‐1 gene polymorphisms with central obesity and metabolic syndrome in a coronary heart disease population. Hum Genet 2008, in press
   Google Scholar
• Padmanabham S, Menni C, Lee Cuk, Brambilla P, Laing S, Sega R, et al. Cardiovascular gene centric association study of metabolic syndrome and ambulatory blood pressure in the PAMELA study. J Hypertens 2008; 26: Suppl 1–S18
   Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860–867
   PubMed Web of Science ®Google Scholar
• Alam I, Lewis K, Stephens JW, Baxter JN. Obesity, metabolic syndrome and sleep apnoea: all pro‐inflammatory states. Obes Rev 2007; 8: 119–127
   PubMed Web of Science ®Google Scholar
• Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25: 909–920
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560–563
   PubMed Web of Science ®Google Scholar
• Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363–2369
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity‐related hypertension. Hypertension 2000; 36: 538–542
   PubMed Web of Science ®Google Scholar
• Grassi G, Dell'Oro R, Quarti‐Trevano F, Scopelliti F, Seravalle G, Paleari F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359–1365
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Quarti‐Trevano F, Scopelliti F, Dell‐Oro R, Bolla G, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 2007; 49: 535–541
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens 1997; 15: 1613–1619
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, van de Borne PJ, Montano N, Dyken ME, Phillips BG, Somers VK. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998; 97: 943–945
   PubMed Web of Science ®Google Scholar
• Wolf J, Lewicka J, Narkiewicz K. Obstructive sleep apnea: an update on mechanisms and cardiovascular consequences. Nutr Metab Cardiovasc Dis 2007; 17: 233–240
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne‐Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Enlg J Med 2002; 346: 393–403
   PubMed Web of Science ®Google Scholar
• Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26: 1891–1900
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Zanchetti A. New‐onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10
   PubMed Web of Science ®Google Scholar